Editorial: Novel preclinical model, biomarker, treatment and drug delivery to address immune evasion in cancer

被引：0
|
作者：
Mai, Chun-Wai [1 ]
Jilkova, Zuzana Macek [2 ,3 ]
Dua, Kamal [4 ,5 ]
Goh, Bey-Hing [6 ,7 ]
机构：
[1] UCSI Univ, Fac Pharmaceut Sci, Kuala Lumpur, Malaysia
[2] Univ Grenoble Alpes, Inst Adv Biosci, CNRS, UMR 5309,INSERM U 1209, Grenoble, France
[3] Univ Hosp Grenoble, Dept Hepatogastroenterol & Digest Oncol, Grenoble, France
[4] Univ Technol Sydney, Grad Sch Hlth, Discipline Pharm, Ultimo, NSW, Australia
[5] Univ Technol Sydney, Fac Hlth, Australian Res Ctr Complementary & Integrat Med, Ultimo, NSW, Australia
[6] Sunway Univ Malaysia, Sunway Biofunct Mol Discovery Ctr, Sch Med & Life Sci, Bandar Sunway, Selangor, Malaysia
[7] Monash Univ Malaysia, Sch Pharm, Biofunct Mol Exploratory Res Grp, Bandar Sunway, Selangor, Malaysia
来源：
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词：
cancer immunology; cancer; modeling; biomarker; treatment;
D O I：
10.3389/fimmu.2024.1486819
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Locoregional drug delivery for cancer therapy: Preclinical progress and clinical translation
    Shaha, Suyog
    Rodrigues, Danika
    Mitragotri, Samir
    Journal of Controlled Release, 2024, 367 : 737 - 767
  • [42] Locoregional drug delivery for cancer therapy: Preclinical progress and clinical translation
    Shaha, Suyog
    Rodrigues, Danika
    Mitragotri, Samir
    JOURNAL OF CONTROLLED RELEASE, 2024, 367 : 737 - 767
  • [43] Best practices and novel approaches for the preclinical development of drug-radiotherapy combinations for cancer treatment
    Prasanna, Pataje G. S.
    Ahmed, Mansoor M.
    Hong, Julie A.
    Coleman, C. Norman
    LANCET ONCOLOGY, 2024, 25 (10): : e501 - e511
  • [44] TRIB3, as a robust prognostic biomarker for HNSC, is associated with poor immune infiltration and cancer cell immune evasion
    Wu, Huadong
    Fu, Zhenzhen
    Li, Hong
    Fang, Feifei
    He, Bin
    Ye, Yujie
    Wu, Heyong
    Xu, Dong
    Zheng, Haoran
    Zhang, Qiang
    FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [45] Novel Drug Delivery Systems for the Treatment of Glaucoma
    Young, Cara E. Capitena
    Kahook, Malik Y.
    Seibold, Leonard K.
    CURRENT OPHTHALMOLOGY REPORTS, 2019, 7 (02) : 143 - 149
  • [46] Novel Drug Delivery Systems for the Treatment of Glaucoma
    Cara E. Capitena Young
    Malik Y. Kahook
    Leonard K. Seibold
    Current Ophthalmology Reports, 2019, 7 : 143 - 149
  • [47] Novel drug delivery systems for the treatment of glaucoma
    Vanrell, Rocio Herrero
    ACTA OPHTHALMOLOGICA, 2022, 100
  • [48] IMMUNOGENIC SYNGENEIC MODEL MC38-OVA FOR THE PRECLINICAL EVALUATION OF IMMUNE EVASION AND CHECKPOINT BLOCKADE
    Wang, Jessie
    Lian, Kaixia
    Zheng, Jia
    Nie, Chenpan
    An, Annie
    Li, Henry
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A348 - A348
  • [49] Novel advances in drug delivery to brain cancer
    Lesniak, MS
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2005, 4 (04) : 417 - 428
  • [50] APPLICATION OF OPTICAL METABOLIC IMAGING IN A NOVEL PRECLINICAL TREATMENT MODEL OF ANAL CANCER.
    Rademacher, B. L.
    Favreau, P. F.
    Conti, M.
    Patin, B. B.
    Carchman, E. H.
    DISEASES OF THE COLON & RECTUM, 2019, 62 (06) : E175 - E176
12345